As of Sep 22
| +1.61 / +2.09%|
The 11 analysts offering 12-month price forecasts for Clovis Oncology Inc have a median target of 97.00, with a high estimate of 125.00 and a low estimate of 52.00. The median estimate represents a +23.47% increase from the last price of 78.56.
The current consensus among 13 polled investment analysts is to Buy stock in Clovis Oncology Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.